Please login to the form below

Not currently logged in
Email:
Password:

Novocure recruits trio of ex-OSI Pharmaceuticals executives

Peter Melnyk, Angela Davies and Laura Benson join company's global commercialisation team

Novocure has added three senior oncology executives to its global management team to support its new tumour treating fields (TTF) cancer therapy.

Peter Melnyk, Angela Davies and Laura Benson join from OSI Pharmaceuticals, which was acquired by Astellas in a 2010 deal.

Melnyk joins Novocure as chief commercial officer responsible for directing the company's global marketing and sales efforts, having previously served as senior vice president for sales and marketing at OSI.

Prior to that he was executive director of oncology at Pfizer and Pharmacia and a director of oncology at Bristol-Myers Squibb.

Angela Davies will serve as Novocure's executive vice president, head of clinical development and medical oncology and will lead the global medical development and clinical strategy for the company.

She was previously senior vice president and chief medical officer of oncology for OSI Pharmaceuticals, prior to which she was an associate professor of medicine at the University of California, Davis Cancer Center.

Finally, Laura Benson joins Novocure as vice president of medical affairs. She was formerly vice president of medical affairs at OSI Pharmaceuticals and prior to that served as associate medical director at Pfizer and Pharmacia.

"Novocure's global commercialisation team is responsible for launching the NovoTTF-100A System under its approved indications for use in the US and Europe, as well as for developing the clinical and commercial plans to lead us into the future," said Asaf Danziger. "I am happy to welcome Peter, Angela and Laura to Novocure and look forward to working with them to make TTF therapy available to cancer patients around the world."

Novocure runs its US operations from Portsouth, New Haven, and has a research centre in Haifa, Israel and headquarters in St Hellier, Jersey.

22nd December 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics